Princeton, United States and Suzhou, China, September 9, 2026 -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its subsidiary, HJB, have entered into a technology licensing and strategic collaboration agreement with WuXi Biologics. Under the agreement, Transcenta will grant WuXi Biologics and its affiliates a non-exclusive license to certain technologies relating to Transcenta’s Highly Intensified Continuous Bioprocessing (“HiCB”) platform and ExcelPro cell culture media. Transcenta will receive an upfront payment of RMB 10 million and will be eligible for milestone payments upon the achievement of specified conditions. Through this collaboration, WuXi Biologics will become Transcenta’s strategic partner for CMC development and supporting molecules across Transcenta’s development pipeline.

PRINCETON, N.J. and SUZHOU, China, May 26, 2026 -- Transcenta Holding Ltd. (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced the receipt of a milestone payment of RMB 7 million from its HiCB (highly intensified continuous bioprocessing) platform out-licensing, alongside significant progress in its CDMO business.

PRINCETON, N.J. and SUZHOU, China, May 21, 2026 -- Transcenta Holding Ltd. (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that its partner Inhibrx Biosciences, Inc. ("Inhibrx") (Nasdaq: INBX) recently reported positive updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). Inhibrx also announced the submission of a Biologics License Application (BLA) to the FDA for ozekibart in conventional chondrosarcoma in April 2026.

Building on this model, Transcenta is expanding its global partner network through additional non-exclusive licensing agreements, helping partners enhance efficiency, lower costs, and increase manufacturing flexibility. Proceeds from these collaborations are reinvested to further strengthen its technology platform and advance its R&D pipeline for next-generation, best-in-class therapeutics.

PRINCETON, N.J. and HANGZHOU, China, December 29, 2025 -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and manufacturing company.